I remember when Glaxo Wellcome hooked up with SmithKline Beecham nearly seven years ago. Then again, that's also the last thing that I remember about GlaxoSmithKline
So I've invited Brian Lawler and Ryan Fuhrmann -- fresh from butting heads last month on Eli Lilly
Man, that name is a mouthful. Now let's see if the bullish Brian and the bearish Ryan can give you an earful of the investing implications of GlaxoSmithKline.
Where do you stand on this high-yielding Income Investor recommendation? Read on and decide for yourself.
- Read the bull argument
- Read the bear argument
- Read the bullish rebuttal
- Read the bearish rebuttal
- Sound off in Motley Fool CAPS
- Vote for the winner